CS273193B2 - Method of new tetrahydrofuro- and -thienol (2,3-c) pyridine production - Google Patents

Method of new tetrahydrofuro- and -thienol (2,3-c) pyridine production Download PDF

Info

Publication number
CS273193B2
CS273193B2 CS712688A CS712688A CS273193B2 CS 273193 B2 CS273193 B2 CS 273193B2 CS 712688 A CS712688 A CS 712688A CS 712688 A CS712688 A CS 712688A CS 273193 B2 CS273193 B2 CS 273193B2
Authority
CS
Czechoslovakia
Prior art keywords
formula
compound
hydrogen
optionally
methyl
Prior art date
Application number
CS712688A
Other languages
Czech (cs)
English (en)
Other versions
CS712688A2 (en
Inventor
Albrecht Dr Harreus
Karl-Heinz Dr Weber
Gerhard Dr Walther
Werner Dr Stransky
Franz J Dr Kuhn
Gunter Dr Schingnitz
Helmut Dr Ensinger
Original Assignee
Boehringer Ingelheim Kg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Kg filed Critical Boehringer Ingelheim Kg
Publication of CS712688A2 publication Critical patent/CS712688A2/cs
Publication of CS273193B2 publication Critical patent/CS273193B2/cs

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CS712688A 1987-10-29 1988-10-27 Method of new tetrahydrofuro- and -thienol (2,3-c) pyridine production CS273193B2 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19873736664 DE3736664A1 (de) 1987-10-29 1987-10-29 Tetrahydro-furo- und -thieno(2,3-c)pyridine, ihre verwendung als arzneimittel und verfahren zu ihrer herstellung

Publications (2)

Publication Number Publication Date
CS712688A2 CS712688A2 (en) 1990-06-13
CS273193B2 true CS273193B2 (en) 1991-03-12

Family

ID=6339349

Family Applications (1)

Application Number Title Priority Date Filing Date
CS712688A CS273193B2 (en) 1987-10-29 1988-10-27 Method of new tetrahydrofuro- and -thienol (2,3-c) pyridine production

Country Status (17)

Country Link
EP (1) EP0314154A3 (da)
JP (1) JPH01157983A (da)
KR (1) KR890006650A (da)
AU (1) AU2443588A (da)
CS (1) CS273193B2 (da)
DD (1) DD283395A5 (da)
DE (1) DE3736664A1 (da)
DK (1) DK603588A (da)
FI (1) FI884947L (da)
HU (1) HU201553B (da)
IL (1) IL88184A0 (da)
NO (1) NO884835L (da)
PL (1) PL275555A1 (da)
PT (1) PT88899B (da)
SU (1) SU1657064A3 (da)
YU (1) YU201288A (da)
ZA (1) ZA888089B (da)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2623810B2 (fr) * 1987-02-17 1992-01-24 Sanofi Sa Sels de l'alpha-(tetrahydro-4,5,6,7 thieno(3,2-c) pyridyl-5) (chloro-2 phenyl) -acetate de methyle dextrogyre et compositions pharmaceutiques en contenant
US5272148A (en) * 1992-09-09 1993-12-21 Hoechst-Roussel Pharmaceuticals Incorporated Heteroarenylpiperazines
US8914114B2 (en) 2000-05-23 2014-12-16 The Feinstein Institute For Medical Research Inhibition of inflammatory cytokine production by cholinergic agonists and vagus nerve stimulation
AU2001267916B2 (en) * 2000-07-06 2004-09-09 Daiichi Sankyo Company, Limited Hydropyridine derivative acid addition salts
JP2005522457A (ja) * 2002-02-26 2005-07-28 ノース ショア−ロング アイランド ジューイッシュ リサーチ インスティチュート 脳ムスカリン性レセプターの刺激による炎症性サイトカイン産生の阻害
US10912712B2 (en) 2004-03-25 2021-02-09 The Feinstein Institutes For Medical Research Treatment of bleeding by non-invasive stimulation
JP2007530586A (ja) 2004-03-25 2007-11-01 ザ ファインスタイン インスティテュート フォー メディカル リサーチ 神経性止血法
US11207518B2 (en) 2004-12-27 2021-12-28 The Feinstein Institutes For Medical Research Treating inflammatory disorders by stimulation of the cholinergic anti-inflammatory pathway
CN101124012B (zh) 2004-12-27 2012-09-05 范因斯坦医学研究院 通过电刺激迷走神经治疗炎症性疾病的装置
TWI392681B (zh) * 2006-04-06 2013-04-11 Daiichi Sankyo Co Ltd 高純度普拉格雷及其酸加成鹽之製法
NZ579993A (en) * 2007-03-02 2012-06-29 Daiichi Sankyo Co Ltd Process for production of prasugrel hydrochloride having high purity
US8391970B2 (en) 2007-08-27 2013-03-05 The Feinstein Institute For Medical Research Devices and methods for inhibiting granulocyte activation by neural stimulation
US9662490B2 (en) 2008-03-31 2017-05-30 The Feinstein Institute For Medical Research Methods and systems for reducing inflammation by neuromodulation and administration of an anti-inflammatory drug
WO2009146030A1 (en) 2008-03-31 2009-12-03 The Feinstein Institute For Medical Research Methods and systems for reducing inflammation by neuromodulation of t-cell activity
US8996116B2 (en) 2009-10-30 2015-03-31 Setpoint Medical Corporation Modulation of the cholinergic anti-inflammatory pathway to treat pain or addiction
US8788034B2 (en) 2011-05-09 2014-07-22 Setpoint Medical Corporation Single-pulse activation of the cholinergic anti-inflammatory pathway to treat chronic inflammation
US9211410B2 (en) 2009-05-01 2015-12-15 Setpoint Medical Corporation Extremely low duty-cycle activation of the cholinergic anti-inflammatory pathway to treat chronic inflammation
CN102573986B (zh) 2009-06-09 2016-01-20 赛博恩特医疗器械公司 用于无导线刺激器的具有袋部的神经封套
US9833621B2 (en) 2011-09-23 2017-12-05 Setpoint Medical Corporation Modulation of sirtuins by vagus nerve stimulation
US11051744B2 (en) 2009-11-17 2021-07-06 Setpoint Medical Corporation Closed-loop vagus nerve stimulation
CN102821814B (zh) 2009-12-23 2015-07-15 赛博恩特医疗器械公司 用于治疗慢性炎症的神经刺激设备和系统
US12172017B2 (en) 2011-05-09 2024-12-24 Setpoint Medical Corporation Vagus nerve stimulation to treat neurodegenerative disorders
US9572983B2 (en) 2012-03-26 2017-02-21 Setpoint Medical Corporation Devices and methods for modulation of bone erosion
US11311725B2 (en) 2014-10-24 2022-04-26 Setpoint Medical Corporation Systems and methods for stimulating and/or monitoring loci in the brain to treat inflammation and to enhance vagus nerve stimulation
WO2016126807A1 (en) 2015-02-03 2016-08-11 Setpoint Medical Corporation Apparatus and method for reminding, prompting, or alerting a patient with an implanted stimulator
US10596367B2 (en) 2016-01-13 2020-03-24 Setpoint Medical Corporation Systems and methods for establishing a nerve block
US11471681B2 (en) 2016-01-20 2022-10-18 Setpoint Medical Corporation Batteryless implantable microstimulators
EP3405255B1 (en) 2016-01-20 2025-12-31 Setpoint Medical Corporation IMPLANTABLE MICROSTIMULATORS AND INDUCTION CHARGING SYSTEMS
EP3405107B1 (en) 2016-01-20 2023-04-12 Setpoint Medical Corporation Control of vagal stimulation
US10583304B2 (en) 2016-01-25 2020-03-10 Setpoint Medical Corporation Implantable neurostimulator having power control and thermal regulation and methods of use
WO2019036470A1 (en) 2017-08-14 2019-02-21 Setpoint Medical Corporation TESTING TEST FOR STIMULATION OF NERVE WAVE
US11260229B2 (en) 2018-09-25 2022-03-01 The Feinstein Institutes For Medical Research Methods and apparatuses for reducing bleeding via coordinated trigeminal and vagal nerve stimulation
AU2020272128B9 (en) 2019-04-12 2025-11-20 Setpoint Medical Corporation Vagus nerve stimulation to treat neurodegenerative disorders
JP2023512447A (ja) 2020-01-13 2023-03-27 ザ ファインスタイン インスティチューツ フォー メディカル リサーチ 脾臓への高密度集束超音波刺激による出血及び出血性疾患の治療
WO2021236977A1 (en) 2020-05-21 2021-11-25 The Feinstein Institutes For Medical Research Systems and methods for vagus nerve stimulation
WO2022245878A1 (en) 2021-05-17 2022-11-24 Setpoint Medical Corporation Neurostimulation parameter authentication and expiration system for neurostimulation
US20250229086A1 (en) 2022-01-20 2025-07-17 Setpoint Medical Corporation Treatment of inflammatory disorders

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2315274A1 (fr) * 1975-06-27 1977-01-21 Parcor Nouveaux derives de la thieno (2,3-c) pyridine, leur preparation et leurs applications
FR2317303A1 (fr) * 1975-07-09 1977-02-04 Parcor Procede de preparation de derives de la tetrahydrothieno (3,2-c) et (2,3-c) pyridine

Also Published As

Publication number Publication date
NO884835L (no) 1989-05-02
DK603588A (da) 1989-04-30
HUT50824A (en) 1990-03-28
NO884835D0 (no) 1988-10-28
EP0314154A2 (de) 1989-05-03
AU2443588A (en) 1989-07-13
HU201553B (en) 1990-11-28
SU1657064A3 (ru) 1991-06-15
DD283395A5 (de) 1990-10-10
FI884947A7 (fi) 1989-04-30
DE3736664A1 (de) 1989-05-11
EP0314154A3 (de) 1990-12-05
FI884947L (fi) 1989-04-30
KR890006650A (ko) 1989-06-15
JPH01157983A (ja) 1989-06-21
YU201288A (en) 1990-08-31
DK603588D0 (da) 1988-10-28
PT88899B (pt) 1993-01-29
IL88184A0 (en) 1989-06-30
CS712688A2 (en) 1990-06-13
PL275555A1 (en) 1989-05-02
FI884947A0 (fi) 1988-10-27
ZA888089B (en) 1990-07-25

Similar Documents

Publication Publication Date Title
CS273193B2 (en) Method of new tetrahydrofuro- and -thienol (2,3-c) pyridine production
US4500525A (en) Pharmacologically active pyrazolo/4,3-c/pyridines
US6800650B2 (en) Pyridine and quinoline derivatives
CA1076571A (en) Tetracyclic derivatives of benzo-pyrido azepines
EP0712387B1 (en) 2-aminoindans as selective dopamine d3 ligands
US3853915A (en) 9-or 10-halo-4h-benzo{8 4,5{9 cyclo-hepta{8 1,2-b{9 thiophen-4-ones
FI94343C (fi) Menetelmä valmistaa terapeuttisesti aktiivisia syklisiä amiinijohdannaisia
US5955495A (en) Method of treating diseases of the CNS
JPH03181461A (ja) 抗不整脈剤
SK31793A3 (en) Pyridine and pyridine n-oxide derivatives of diaryl methyl piperidines and piperazines and compositions and methods of use thereof
DK156057B (da) Analogifremgangsmaade til fremstilling af trisubstituerede 1-phenyl-2,3,4,5-tetrahydro-1h-3-benzazepinforbindelser
GB2088869A (en) 8-arylalkyl-3-phenyl-3-nortropanols
IE57057B1 (en) Carboxamides,process for their preparation and pharmaceutical preparations containing them
DK153844B (da) Analogifremgangsmaade til fremstilling af 1,2,3,5-tetrahydroimidazothienopyrimidin-2-oner
US3227716A (en) Therapeutically-active dibenzocycloheptane derivatives
KR20010102006A (ko) Ａβ 원섬유 형성 억제제로서의 피페리딘 및 피페라진유도체
JPS6040422B2 (ja) 置換１‐アルキルチオフエニル―２，３，４，５―テトラヒドロ―１ｈ―３―ベンズアゼピン化合物
EP0233049A1 (en) 2,3,4,8,9,9a-Hexahydro-4-aryl-1H-indeno[1,7-cd]azepines
US4206210A (en) Alkylthio-7,8-dihdroxy-1-phenyl-2,3,4,5-tetrahydro-1H-3-benzazepines having dopaminergic activity
US4322423A (en) 4-Phenyl-4,5,6,7-tetrahydro-thieno(2,3-C)pyridines and salts thereof
JPH03120271A (ja) 抗虚血活性を有するフェニルアルキルアミン誘導体
JPS62289582A (ja) 置換チアシクロアルケノ〔３，２−ｂ〕ピリジン類
HU208970B (en) Process for producing new thienloxyalkyl derivatives and pharmaceutical compositions comprising same
CA1138864A (en) 4-phenyl-4,5,6,7-tetrahydro-pyrrolo[2,3-c] pyridines, process for the production thereof and pharmaceutical compositions
DK160049B (da) 6-phenethylaminoalkyl-furo-(3,4-c)-pyridin-derivater, og laegemidler indeholdende saadanne forbindelser